Related Experiment Videos
Nitric oxide and portal hypertension
Juan González-Abraldes1, Juan Carlos García-Pagán, Jaime Bosch
1Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Spain.
Metabolic Brain Disease
|February 27, 2003
Summary
Liver cirrhosis increases hepatic resistance and portal hypertension due to nitric oxide (NO) deficiency. While NO blockade may reduce splanchnic vasodilation, it could worsen hepatic resistance and cirrhosis progression.
Area of Science:
- Hepatology
- Vascular Biology
- Pharmacology
Background:
- Liver cirrhosis initiates portal hypertension through increased hepatic resistance, stemming from intrahepatic microcirculation distortion.
- Cirrhosis-induced architectural changes impair nitric oxide (NO) production, elevating vascular tone, hepatic resistance, and portal pressure.
- Splanchnic arterial circulation paradoxically exhibits increased NO production, causing vasodilation, increased portal inflow, and contributing to portal hypertension.
Purpose of the Study:
- To investigate the dual role of nitric oxide (NO) in liver cirrhosis and portal hypertension.
- To evaluate the therapeutic potential of selective hepatic NO delivery versus systemic NO blockade.
Main Methods:
- Analysis of nitric oxide (NO) production in hepatic and splanchnic circulations in liver cirrhosis.
- Assessment of the effects of systemic NO blockade on hepatic resistance, portal inflow, and portal pressure.
- Consideration of potential impacts of NO modulation on cirrhosis progression.
Main Results:
- Deficient NO production in the liver increases hepatic resistance and portal pressure.
- Increased NO production in the splanchnic circulation causes vasodilation and contributes to portal hypertension.
- Systemic NO blockade may not effectively reduce portal pressure due to increased hepatic resistance and potential harm to cirrhosis progression.
Conclusions:
- Nitric oxide (NO) plays a complex, opposing role in the pathophysiology of liver cirrhosis and portal hypertension.
- Targeted hepatic NO delivery may offer a therapeutic advantage over systemic NO blockade.
- Caution is advised regarding systemic NO blockade in cirrhosis patients due to potential adverse effects on hepatic resistance and disease progression.